As of 2026-03-31, the Relative Valuation of TCR2 Therapeutics Inc (TCRR) is (82.25) USD. This relative valuation is based on P/E multiples. With the latest stock price at 1.48 USD, the upside of TCR2 Therapeutics Inc based on Relative Valuation is -5657.6%.
The range of the Relative Valuation is (75.69) - (87.82) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 18.2x - 22.5x | 19.6x |
| Forward P/E multiples | 17.4x - 21.1x | 20.0x |
| Fair Price | (75.69) - (87.82) | (82.25) |
| Upside | -5214.1% - -6033.7% | -5657.6% |
| Date | P/E |